Improved overall survival in melanoma with combined dabrafenib and trametinib.

By C. Robert, B. Karaszewska, J. Schachter, P. Rutkowski, A. Mackiewicz, D. Stroiakovski, M. Lichinitser, R. Dummer, F. Grange, L. Mortier and 17 more. New England Journal of Medicine, 2015

2,453 citations recorded by the source corpus.

Subfields: Molecular Biology, Oncology, Ophthalmology

View Paper: https://www.semanticscholar.org/paper/1a3feeab5891220823431832ac447910fbc520ca

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Molecular Biology

1. Guido Kroemer
2. L. Galluzzi
3. Oliver Kepp
4. L. Zitvogel
5. Douglas R. Green
6. Beth Levine
7. Simone Fulda
8. Thomas G. Cotter

In Oncology

1. Guido Kroemer
2. L. Galluzzi
3. L. Zitvogel
4. Padmanee Sharma
5. Oliver Kepp
6. James P. Allison
7. K. Flaherty
8. Georgina V. Long

Citations in the corpus

• Cutaneous melanoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†. (2019, background): “BRAF/MEK double inhibition is superior to single-agent BRAF in terms of response rates, PFS and OS [68-70].”
• Immunological Effects of Conventional Chemotherapy and Targeted Anticancer Agents. (2015, background): “…kinase (BRAF), such as the V600E and the V600K substitutions, respond to a combinatorial chemotherapeutic regimens involving one BRAF inhibitor (e.g., vemurafenib, dabrafenib) and one inhibitor of mitogen-activated protein kinase (MAPK) signaling (e.g., trametinib) (Robert et al., 2015).”
• A standardised, generic, validated approach to stratify the magnitude of clinical benefit that can be anticipated from anti-cancer therapies: the European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS). (2015, neutral): “89) 17% reduction skin cancer 4* [144]”
• Evolution of Cancer Pharmacological Treatments at the Turn of the Third Millennium (2018, background): “Among the selective serine/threonine kinase inhibitors, BRAF inhibitors (Vemurafenib and Dabrafenib) and MEK inhibitors (Trametinib and Cobimetinib) are widely used in clinical practice for the treatment of mutated BRAFV600E melanomas, providing significant improvement in survival rates (Robert et a”
• Melanoma Staging: Evidence-Based Changes in the American Joint Committee on Cancer Eighth Edition Cancer Staging Manual (2017, methodology): “as well as stratification and analysis, are often based on the presence/absence of CNS disease.(6-20,73,74) Therefore, this additional level of granularity in the M category “maps” bet-”
• Molecular profiling for precision cancer therapies (2020, background): “bination of BRAF and MEK inhibitors in BRAF mutant melanoma) [32, 33].”